{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:42:53Z","timestamp":1790473373541,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007210","name":"RWTH Aachen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007210","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To examine whether early combination lipid-lowering therapy after acute coronary syndrome (ACS) should be considered as a standard approach. The review assesses current international guideline recommendations, supporting clinical evidence, and real-world implementation gaps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent European and U.S. guidelines emphasise lower low-density lipoprotein-cholesterol (LDL-C) targets and suggest earlier use of combination therapy. Data from randomised trials, registry-based emulations, and observational cohorts demonstrate that early initiation of high-intensity regimens improves LDL-C goal attainment and may reduce the recurrence of cardiovascular events. However, registry data reveal substantial global undertreatment and limited treatment intensification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Early combination therapy represents a pragmatic strategy to accelerate LDL-C goal achievement after ACS. While this approach could narrow current treatment gaps, it must be balanced against the trend toward personalised, risk-based lipid management. Future research should address how simplified treatment algorithms can coexist with individualised care frameworks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-026-02346-8","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:11:49Z","timestamp":1770106309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care?"],"prefix":"10.1007","volume":"28","author":[{"given":"Julia","family":"Brandts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-634X","authenticated-orcid":false,"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"1","key":"2346_CR1","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1038\/s41598-023-30597-w","volume":"13","author":"A Ulvenstam","year":"2023","unstructured":"Ulvenstam A, Graipe A, Irewall A-L, S\u00f6derstr\u00f6m L, Mooe T. Incidence and predictors of cardiovascular outcomes after acute coronary syndrome in a population-based cohort study. Sci Rep. 2023;13(1):3447.","journal-title":"Sci Rep"},{"issue":"3","key":"2346_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/clc.23160","volume":"42","author":"S Li","year":"2019","unstructured":"Li S, Peng Y, Wang X, Qian Y, Xiang P, Wade SW, Guo H, Lopez JAG, Herzog CA, Handelsman Y. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older medicare population. Clin Cardiol. 2019;42(3):391\u20139.","journal-title":"Clin Cardiol"},{"issue":"19","key":"2346_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163\u201370.","journal-title":"Eur Heart J"},{"issue":"9841","key":"2346_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"CT Trialists","year":"2012","unstructured":"Trialists CT. The effects of Lowering LDL cholesterol with Statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet"},{"issue":"14","key":"2346_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","volume":"39","author":"KC Koskinas","year":"2017","unstructured":"Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, R\u00e4ber L, Mach F, Windecker S. Effect of Statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2017;39(14):1172\u201380.","journal-title":"Eur Heart J"},{"key":"2346_CR6","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174\u2008000 participants in 27 randomised trials. The Lancet 2015, 385(9976):1397\u20131405.","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"2346_CR7","doi-asserted-by":"crossref","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J 2025.","DOI":"10.1016\/j.atherosclerosis.2025.120479"},{"issue":"1","key":"2346_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J. 2019;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"34","key":"2346_CR9","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European society of cardiology and 12 medical societies with the special contribution of the European association of preventive cardiology (EAPC). Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"38","key":"2346_CR10","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan G-A, Dweck MR, Galbraith M, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European society of cardiology (ESC). Eur Heart J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"issue":"22","key":"2346_CR11","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","volume":"85","author":"SV Rao","year":"2025","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2025;85(22):2135\u2013237.","journal-title":"J Am Coll Cardiol"},{"issue":"10349","key":"2346_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"B-K Kim","year":"2022","unstructured":"Kim B-K, Hong S-J, Lee Y-J, Hong SJ, Yun KH, Hong B-K, Heo JH, Rha S-W, Cho Y-H, Lee S-J, et al. Long-term efficacy and safety of moderate-intensity Statin with Ezetimibe combination therapy versus high-intensity Statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380\u201390.","journal-title":"Lancet"},{"issue":"13","key":"2346_CR13","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1001\/jama.2023.2487","volume":"329","author":"S-J Hong","year":"2023","unstructured":"Hong S-J, Lee Y-J, Lee S-J, Hong B-K, Kang WC, Lee J-Y, et al. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial. JAMA. 2023;329(13):1078\u201387.","journal-title":"JAMA"},{"issue":"22","key":"2346_CR14","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"18","key":"2346_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"key":"2346_CR16","doi-asserted-by":"crossref","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJ, Thompson PD, Libby P, Cho L, Plutzky J. Bempedoic acid and cardiovascular outcomes in Statin-Intolerant patients. N Engl J Med 2023.","DOI":"10.1001\/jama.2023.9696"},{"issue":"18","key":"2346_CR17","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, Losdat S, H\u00e4ner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns R-J, Ondracek AS, et al. Effect of Alirocumab added to High-Intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771\u201381.","journal-title":"JAMA"},{"issue":"7","key":"2346_CR18","first-page":"1308","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman J-PR, Hermanides RS, et al. Effect of Evolocumab on coronary plaque phenotype and burden in Statin-Treated patients following myocardial infarction. JACC: Cardiovasc Imaging. 2022;15(7):1308\u201321.","journal-title":"JACC: Cardiovasc Imaging"},{"issue":"1\u20132","key":"2346_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0021-9150(87)90094-3","volume":"68","author":"KM Anderson","year":"1987","unstructured":"Anderson KM, Wilson PW, Garrison RJ, Castelli WP. Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample the Framingham offspring study. Atherosclerosis. 1987;68(1\u20132):59\u201366.","journal-title":"Atherosclerosis"},{"issue":"6","key":"2346_CR20","first-page":"239","volume":"29","author":"JAG Gerique","year":"2017","unstructured":"Gerique JAG, Gonzalez IF, Herrera MAR, Pablos DL, Ballesteros BM, Sardina RG, de la C\u00e1mara AG. Improvement of serum lipids concentration in a general population historical cohort. Why? Cl\u00ednica E Investigaci\u00f3n En Arteriosclerosis. 2017;29(6):239\u201347.","journal-title":"Why? Cl\u00ednica E Investigaci\u00f3n En Arteriosclerosis"},{"issue":"11","key":"2346_CR21","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2020","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, et al. EU-Wide Cross-Sectional observational study of Lipid-Modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2020;28(11):1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"key":"2346_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. Treatment gaps in the implementation of LDL cholesterol control among high-and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study The Lancet Regional Health\u2013Europe. 2023. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624.","journal-title":"The Lancet Reg Health\u2013Eur"},{"issue":"15","key":"2346_CR23","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","volume":"31","author":"KK Ray","year":"2024","unstructured":"Ray KK, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferri\u00e8res J, Laufs U, Mostaza JM, Nanchen D, Bardet A. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. 2024;31(15):1792\u2013803.","journal-title":"Eur J Prev Cardiol"},{"issue":"13","key":"2346_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00508-023-02221-4","volume":"135","author":"H Toplak","year":"2023","unstructured":"Toplak H, Bilitou A, Alber H, Auer J, Clodi M, Ebenbichler C, Flie\u00dfer-G\u00f6rzer E, Gelsinger C, Hanusch U, Ludvik B, et al. Simulation of bempedoic acid and Ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients. Wiener Klinische Wochenschrift. 2023;135(13):364\u201374.","journal-title":"Wiener Klinische Wochenschrift"},{"key":"2346_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100665","author":"J Brandts","year":"2023","unstructured":"Brandts J, Bray S, Villa G, Catapano AL, Poulter NR, Vallejo-Vaz AJ, et al. Optimal implementation of the 2019 ESC\/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: A simulation based on the DA VINCI study.The Lancet Regional Health\u2013Europe. 2023. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100665.","journal-title":"The Lancet Reg Health\u2013Eur"},{"key":"2346_CR26","doi-asserted-by":"crossref","unstructured":"Brandts J, Barkas F, De Bacquer D, Jennings C, De Backer GG, Kotseva K, Ryden L, Lip GY, Erlund I, Ganly S. International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study. Eur J Prev Cardiol 2025:zwaf388.","DOI":"10.1093\/eurjpc\/zwaf388"},{"issue":"9","key":"2346_CR27","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1007\/s00392-022-02147-3","volume":"112","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Samadifar B, Maloku A, Haxhikadrija P, Geiling J-A, R\u00f6mer R, Lauer B, M\u00f6bius-Winkler S, Otto S, Schulze PC, et al. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (Jena auf Ziel). Clin Res Cardiol. 2023;112(9):1212\u20139.","journal-title":"Clin Res Cardiol"},{"key":"2346_CR28","doi-asserted-by":"crossref","unstructured":"Haertel F, Makhmudova U, Geiling J-A, Lauer B, M\u00f6bius-Winkler S, Otto S, Schulze PC, Weing\u00e4rtner O. Less intensive lipid-lowering therapy after ST-elevation myocardial infarction is associated with cardiovascular events: 2-year follow-up of Jena auf Ziel. Clin Res Cardiol 2025.","DOI":"10.1007\/s00392-025-02736-y"},{"key":"2346_CR29","doi-asserted-by":"crossref","unstructured":"Margret Leosdottir M, PHD,a,b Jessica Schubert, MD,c Julia Brandts, MD,d,e Stefan Gustafsson, PHD,f, Thomas Cars P, f Johan Sundstr\u00f6m, MD, PHD,c Tomas Jernberg, MD, PHD,g Kausik, Ray K. MBCHB, MD, FMEDSCI,d,h, Emil Hagstr\u00f6m M, PHDc,: Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry. J Am Coll Cardiol\u00a02025, in press.","DOI":"10.1016\/j.jacc.2025.02.007"},{"issue":"9","key":"2346_CR30","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","volume":"3","author":"MS Sabatine","year":"2018","unstructured":"Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-Density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol. 2018;3(9):823\u20138.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2346_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11883-024-01270-y","volume":"27","author":"J Brandts","year":"2024","unstructured":"Brandts J, M\u00fcller-Wieland D. Debate: lipid-lowering therapies and diabetes development. Curr Atheroscler Rep. 2024;27(1):24.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"2346_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","volume":"161","author":"JL Goldstein","year":"2015","unstructured":"Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161\u201372.","journal-title":"Cell"},{"issue":"7","key":"2346_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, et al. Cognitive function in a randomized trial of Evolocumab. N Engl J Med. 2017;377(7):633\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"2346_CR34","doi-asserted-by":"publisher","first-page":"EVIDoa2400112","DOI":"10.1056\/EVIDoa2400112","volume":"4","author":"A Zimerman","year":"2025","unstructured":"Zimerman A, O\u2019Donoghue ML, Ran X, Im K, Ott BR, Mach F, Zavitz K, Kurtz CE, Monsalvo ML, Wang B. Long-term cognitive safety of achieving very low LDL cholesterol with Evolocumab. NEJM Evid. 2025;4(1):EVIDoa2400112.","journal-title":"NEJM Evid"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02346-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02346-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02346-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:49Z","timestamp":1781632369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02346-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2346"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02346-8","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"J.B. has received research grants from Amgen, AstraZeneca, and Sanofi; and consulting fees and\/or speaker honoraria from Amgen, AstraZeneca, Berlin Chemie, Daiichi Sankyo, Eli Lilly, Novartis, Novo Nordisk, and Sanofi. N.M. received through his institution contracted fees and travel support from Boehringer Ingelheim and Novo Nordisk; consulting fees through his institution from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, MSD, Novo Nordisk, Sanofi Aventis; and payment or honoraria for lectures, presentations, speaker bureaus, and travel support from AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Lilly, MSD, Novo Nordisk, and Sanofi Aventis. N.M. is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TRR 219; Project-ID 322900939 [M03, M05].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"19"}}